Navigation Links
XENAZINE(R) (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington's Disease
Date:8/15/2008

WASHINGTON, Aug. 15 /PRNewswire/ -- Prestwick Pharmaceuticals, Inc., a privately-held pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved XENAZINE(R) (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). XENAZINE is the first and only FDA-approved treatment for any symptom of HD and is expected to be available later this year.

"Until today, physicians and patients had no FDA-approved treatments for Huntington's disease," said Fred Marshall, M.D., chief of the geriatric neurology unit at the University of Rochester. "Within a few months, for the first time, physicians will be able to offer these critically-ill patients a safe and effective medication to treat their chorea."

A double-blind, placebo-controlled, Phase 3 study found that XENAZINE significantly reduced patients' chorea burden, improved global outcome scores, and was generally safe and well tolerated. XENAZINE will be marketed under an FDA-approved Risk Evaluation and Mitigation Strategy to decrease the risk of depression and suicidal ideation that may be associated with the drug, and are often pre-existing conditions in Huntington's disease patients.

In December 2007, patients, advocates, and caregivers spoke in favor of approving XENAZINE at a meeting of the FDA's Peripheral and Central Nervous System Drugs Advisory Committee. The committee voted 11-0 to recommend approval of the drug.

"We are pleased that the FDA has approved XENAZINE, the first medication for the Huntington's disease patients and physicians who are in desperate need of a treatment," said George F. Horner, III, president and chief executive officer of Prestwick. "The approval of XENAZINE is a huge advancement for the HD community, and we thank them for their contributions in helping to make this important product available in the United States."

XENAZINE has been available in a number of countries in Europe for mo
'/>"/>

SOURCE Prestwick Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. $52.5 Million Settlement Against Sepracor Inc. Approved
2. FDA Cracks Down on Unapproved Cough Medicines
3. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
4. Optometry-Backed Vision Care for Kids Act Approved by U.S. House
5. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
6. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
7. Barrs Generic Version of Estrostep(R) Fe Tablets Approved
8. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
9. Pennsylvania American Waters Rate Case Approved
10. RNs Statement on Death of Nataline Sarkisyan: CIGNA Should Have Listened to her Doctors and Approved the Transplant a Week Ago
11. Hiemstra Approved to Manufacture Medical Devices in New CER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Seattle, WA (PRWEB) , ... July 31, 2015 , ... ... rapidly transforming the way we treat aging diseases. , BioViva announces it has ... to treat patients with Alzheimer’s Disease (AD) and find a cure. MaxLife will grant ...
(Date:7/31/2015)... ... 2015 , ... The Heart Fit Clinic has increased a patient's fitness level ... of 150 beats versus 100 beats, this is a big deal," says Diamond Fernandes, ... back to patients with heart disease," he adds. People with angina are able to ...
(Date:7/31/2015)... ... July 31, 2015 , ... Patients with higher levels ... a study published today in Nature Communications and led by researchers from the Icahn ... that variations in the gene RTN1 led to greater production of the related RNT1 ...
(Date:7/31/2015)... ... ... Indosoft, Inc., is pleased to announce a major update to its agent interface ... ACD system for Asterisk-based call centers . The new features make it easier ... agent only when wanted, and allows for validation of data as the agent enters ...
(Date:7/31/2015)... ... 2015 , ... According to WFLA on July 16th, Sarasota has ... eventual overdoses. Thricefold deaths have held steady over the last “couple of months” according ... epidemic, which was spurred by the crackdown of prescription painkillers. Many users who were ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3
... 15 The World Health Organization has increased the pandemic alert ... flu, the first time it has been raised to this level ... themselves, but need not be fearful. The outbreak is considered ... that influenza A (H1N1) is necessarily causing more serious infections, or ...
... ... Staffing Solutions , ... Alpharetta, GA (Vocus) June 14, 2009 -- "Thomas McKeever has been ... marketing thrust--introducing a more streamlined approach to physician staffing at prominent hospitals and ...
... generate infection-fighting proteins called antibodies that either block infection ... disease. Attempts to create a vaccine that induces antibodies ... far been unsuccessful. But several recent studies suggest promising ... HIV vaccine, according to John R. Mascola, M.D., deputy ...
... information exchange , , TORONTO, June 14 ... Toronto this week, Siemens Healthcare will highlight Symbia.net*, the ... for anytime, anywhere processing and reading. Show attendees are ... (#1024). , , (Photo: ...
... can occur, , SUNDAY, June 14 (HealthDay News) -- The ... attention to the issue of brain injury and raised important ... or a loved one. , Richardson died hours after taking ... picked herself up from the fall and refused medical attention, ...
... January to May 2009 sees ... , ... the chairman of MYA Cosmetic Surgery Ltd. and former owner of Transform Medical Group, ... eyelid surgery. John Ryan, 59, has decided to have the procedure which he feels will make ...
Cached Medicine News:Health News:As World Health Organization Raises Influenza A (H1N1) Pandemic Alert to Level Six, Hygiene Council Recommends Simple Steps to Help Protect Families from Illness 2Health News:As World Health Organization Raises Influenza A (H1N1) Pandemic Alert to Level Six, Hygiene Council Recommends Simple Steps to Help Protect Families from Illness 3Health News:Thomas McKeever to Spearhead Jackson & Coker's National Accounts Division 2Health News:Thomas McKeever to Spearhead Jackson & Coker's National Accounts Division 3Health News:NIAID media availability: New strategy proposed for designing antibody-based HIV vaccine 2Health News:Symbia.net - Hotspot for Remote Access 2Health News:Symbia.net - Hotspot for Remote Access 3Health News:For Every Blow to the Head, Quick Action Is Urged 2Health News:For Every Blow to the Head, Quick Action Is Urged 3Health News:Cosmetic Surgery Pioneer Goes Under the Knife 2Health News:Cosmetic Surgery Pioneer Goes Under the Knife 3
(Date:7/31/2015)... 2015 The Physician-Patient Alliance for Health ... 28, 2015, "Surviving Your Hospital Stay: Physician-Patient Alliance ... Safety." A sentence was omitted from ... "PPAHS is a member of the National Coalition ... information on the National Coalition to Promote Continuous Monitoring ...
(Date:7/31/2015)... Egalet Corporation (Nasdaq: EGLT ) ... on developing, manufacturing and marketing innovative pain treatments, ... underwritten public offering of 7,666,667 shares of its ... $11.25 per share. The shares of common stock ... the exercise in full by the underwriters of ...
(Date:7/31/2015)... , July 31, 2015 ... for video, data and cloud computing operators has ... leading pharma giant for Internet of Things (IoT) ... applications offered on subscription model.      ... giant is striving for business innovations to make ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... Pilot Study Demonstrates 50% ... ANNAPOLIS, Md., March 29, 2007,/PRNewswire-FirstCall/ -- Medarex, Inc. ... a privately held,biotechnology company dedicated to the development ... human,monoclonal antibody product candidate being developed for the,prevention ...
... DIEGO--(BUSINESS WIRE)--Mar 29, 2007 - ACADIA Pharmaceuticals,Inc. ... to fuel drug discovery and clinical,development of ... announced that the company will present at ... from,March 28 through April 1, 2007, in ...
Cached Medicine Technology:Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 8ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 2ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 3ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 4ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 5
Introducing the Guidant HEARTSTRING Proximal Seal System. A surgically intuitive system that meets the challenge of clampless hemostasis with a design that is elegant in its simplicity and profound i...
... The Nidek's ophthalmic Nd: YAG laser YC-1600 ... system of superb versatility and clinical performance., ... Laser (1064nm),, Lightweight Model ,Further weight ... convenient setting in your office.,, Aiming ...
... system, developed by Given Imaging of Israel, is ... a grape. Weighing in at only four grams, ... LED lights, battery and radio transmitter coated by ... digestive enzymes. Internal gastric images are transmitted to ...
... catheter-free Bravo pH Monitoring System ... testing is done. Bravo allows ... diet and activities during pH ... catheter-free, the added convenience for ...
Medicine Products: